These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 20696926)

  • 21. Detection and characterization of aggregates, prefibrillar amyloidogenic oligomers, and protofibrils using fluorescence spectroscopy.
    Lindgren M; Sörgjerd K; Hammarström P
    Biophys J; 2005 Jun; 88(6):4200-12. PubMed ID: 15764666
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Etiology and pathogenesis of the muscular dystrophies.
    Van den Bergh PY; Tomé FM; Fardeau M
    Acta Neurol Belg; 1995; 95(3):123-41. PubMed ID: 7484050
    [TBL] [Abstract][Full Text] [Related]  

  • 23. On dystrophin abundance and C-terminal missense mutations in dystrophinopathies.
    Oexle K; Heyer R
    Ann Neurol; 1999 Jul; 46(1):137-8. PubMed ID: 10401797
    [No Abstract]   [Full Text] [Related]  

  • 24. Stability of dystrophin STR fragments in relation to junction helicity.
    Mirza A; Menhart N
    Biochim Biophys Acta; 2008 Sep; 1784(9):1301-9. PubMed ID: 18589007
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dystrophin analysis using a panel of anti-dystrophin antibodies in Duchenne and Becker muscular dystrophy.
    Muntoni F; Mateddu A; Cianchetti C; Marrosu MG; Clerk A; Cau M; Congiu R; Cao A; Melis MA
    J Neurol Neurosurg Psychiatry; 1993 Jan; 56(1):26-31. PubMed ID: 8429320
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression, purification and characterization of fourth FAS1 domain of TGFβIp-associated corneal dystrophic mutants.
    Elavazhagan M; Lakshminarayanan R; Zhou L; Ting LW; Tong L; Beuerman RW; Chaurasia SS; Mehta JS
    Protein Expr Purif; 2012 Jul; 84(1):108-15. PubMed ID: 22575305
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structure and dynamics of the alpha-lactalbumin molten globule: fluorescence studies using proteins containing a single tryptophan residue.
    Chakraborty S; Ittah V; Bai P; Luo L; Haas E; Peng Z
    Biochemistry; 2001 Jun; 40(24):7228-38. PubMed ID: 11401570
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Muscular dystrophies detected by immunophenotyping and genotype analysis (mRNA and DNA)].
    Lukás Z; Vojtísková M; Fajkusová L; Bednarík J; Kadanka Z; Hájek J; Hermanová M; Vohánka S; Vytopil M
    Cesk Patol; 2001 Nov; 37(4):137-45. PubMed ID: 11813630
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disease-associated substitutions in the filamin B actin binding domain confer enhanced actin binding affinity in the absence of major structural disturbance: Insights from the crystal structures of filamin B actin binding domains.
    Sawyer GM; Clark AR; Robertson SP; Sutherland-Smith AJ
    J Mol Biol; 2009 Jul; 390(5):1030-47. PubMed ID: 19505475
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immobilization of Dystrophin and Laminin α2-Chain Deficient Zebrafish Larvae In Vivo Prevents the Development of Muscular Dystrophy.
    Li M; Arner A
    PLoS One; 2015; 10(11):e0139483. PubMed ID: 26536238
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evidence for a mechanism of amyloid formation involving molecular reorganisation within native-like precursor aggregates.
    Plakoutsi G; Bemporad F; Calamai M; Taddei N; Dobson CM; Chiti F
    J Mol Biol; 2005 Aug; 351(4):910-22. PubMed ID: 16024042
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Lessons of dystrophin].
    Desnuelle C
    Presse Med; 1994 May; 23(19):896-900. PubMed ID: 7937619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Crystal structure of the actin-binding region of utrophin reveals a head-to-tail dimer.
    Keep NH; Winder SJ; Moores CA; Walke S; Norwood FL; Kendrick-Jones J
    Structure; 1999 Dec; 7(12):1539-46. PubMed ID: 10647184
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structural Stability and Local Dynamics in Disease-Causing Mutants of Human Apolipoprotein A-I: What Makes the Protein Amyloidogenic?
    Das M; Wilson CJ; Mei X; Wales TE; Engen JR; Gursky O
    J Mol Biol; 2016 Jan; 428(2 Pt B):449-62. PubMed ID: 26562506
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Coiled-coil regions in the carboxy-terminal domains of dystrophin and related proteins: potentials for protein-protein interactions.
    Blake DJ; Tinsley JM; Davies KE; Knight AE; Winder SJ; Kendrick-Jones J
    Trends Biochem Sci; 1995 Apr; 20(4):133-5. PubMed ID: 7770909
    [No Abstract]   [Full Text] [Related]  

  • 36. The frequency of patients with dystrophin abnormalities in a limb-girdle patient population.
    Arikawa E; Hoffman EP; Kaido M; Nonaka I; Sugita H; Arahata K
    Neurology; 1991 Sep; 41(9):1491-6. PubMed ID: 1842672
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Functional capacity of dystrophins carrying deletions in the N-terminal actin-binding domain.
    Banks GB; Gregorevic P; Allen JM; Finn EE; Chamberlain JS
    Hum Mol Genet; 2007 Sep; 16(17):2105-13. PubMed ID: 17588958
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dystrophin, the protein that promotes membrane resistance.
    Fabbrizio E; Bonet-Kerrache A; Limas F; Hugon G; Mornet D
    Biochem Biophys Res Commun; 1995 Aug; 213(1):295-301. PubMed ID: 7639748
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The differential diagnosis of the human dystrophinopathies and related disorders.
    Kakulas BA
    Curr Opin Neurol; 1996 Oct; 9(5):380-8. PubMed ID: 8894415
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Macromolecular crowding induces a molten globule state in the C-terminal domain of histone H1.
    Roque A; Ponte I; Suau P
    Biophys J; 2007 Sep; 93(6):2170-7. PubMed ID: 17513371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.